Mediators of Inflammation

Mediators of Inflammation is a fully open-access immunology journal published by Wiley, founded in 1992, covering the cytokines, lipid mediators and adhesion molecules that orchestrate inflammation, with a 2025 Journal Impact Factor of 4.9.《炎症介质》（Mediators of Inflammation）由（Wiley）出版，1992 年创刊，为完全开放获取的免疫学期刊，涵盖驱动炎症的细胞因子、脂质介质与黏附分子，2025 年期刊影响因子为 4.9。

Scope

• Cytokines and chemokines are the largest group, from interleukins and tumour necrosis factor to the chemotactic signals that recruit leukocytes.细胞因子与趋化因子是最大的门类，从白细胞介素、肿瘤坏死因子到招募白细胞的趋化信号。
• Histamine and bradykinin represent the classical vasoactive mediators that act within minutes of tissue injury.组胺与缓激肽代表经典的血管活性介质，在组织损伤后数分钟内起作用。
• Prostaglandins, leukotrienes and platelet-activating factor cover the eicosanoid and phospholipid branches of the inflammatory cascade.前列腺素、白三烯与血小板活化因子，涵盖炎症级联中的类花生酸与磷脂分支。
• Biological response modifiers and inflammasomes are explicitly named in the scope, linking mediator biology to innate immune activation.生物反应调节剂与炎性小体在范围中明确列出，把介质生物学与先天免疫激活联系起来。
• The family of cell adhesion-promoting molecules is included, covering the adhesion steps that let circulating cells enter inflamed tissue.细胞黏附促进分子家族在范围之内，涉及循环细胞进入炎症组织的黏附步骤。
• The journal favours work that shows how a mediator acts, how its signalling is resolved, or how it might be targeted therapeutically.刊物青睐阐明介质如何起作用、信号如何消退或如何成为治疗靶点的研究。
• Original research and review articles are accepted, while descriptive papers without a novel application or insight may be declined.接受原创研究与综述，缺乏新应用或新见解的描述性稿件可能不予考虑。

History

• The journal was founded in 1992 by Rapid Communications of Oxford and published from Oxford, with Volume 1 indexed in PubMed from its first issue.刊物于 1992 年由（Rapid Communications of Oxford）创办并在牛津出版，第 1 卷自创刊号起即被（PubMed）收录。
• It later moved to Hindawi, which issued it under the 10.1155 DOI prefix and switched to annual volumes with article numbers instead of page ranges.其后转由（Hindawi）出版，使用（10.1155）的（DOI）前缀，并改为按年成卷、以文章编号替代连续页码。
• Wiley acquired Hindawi in January 2021 for 298 million US dollars, and from 2023 the journal has been published from Hoboken, New Jersey.（Wiley）于 2021 年 1 月以 2.98 亿美元收购（Hindawi），自 2023 年起该刊在（New Jersey）的（Hoboken）出版。
• It now belongs to the Wiley Forward Series, a group of titles run on a streamlined workflow with a strong emphasis on research integrity.该刊现属（Wiley）的（Forward Series），这一系列以精简流程与科研诚信为重点。
• The print edition was bimonthly, and the journal now publishes one annual volume with continuous article numbering while keeping ISSN 0962-9351 and 1466-1861.纸本原为双月刊，现按年一卷、文章连续编号，并保留（ISSN 0962-9351）与（1466-1861）。
• It is gold open access under CC BY with an article processing charge of 3,340 US dollars, and MEDLINE coverage began with Volume 7 in 1998.刊物以（CC BY）许可金色开放获取，文章处理费为 3,340 美元，（MEDLINE）收录始于 1998 年第 7 卷。
• Its 2025 Journal Impact Factor is 4.9, up from 4.2 in 2024, with a CiteScore of 8 and a Q2 placing at rank 54 of 183 in immunology.2025 年期刊影响因子为 4.9，高于 2024 年的 4.2，（CiteScore）为 8，在免疫学类别位列（Q2），排名 54/183。

Editors

• Anshu Agrawal of the University of California is Chief Editor, and her research centres on immune ageing.（Anshu Agrawal）为主编，任职于（University of California），研究方向为免疫衰老。
• Anuja Salgaonkar, based at Wiley in India, serves as Assistant Editor and supports the editorial office.（Anuja Salgaonkar）常驻（Wiley）印度办公室，任助理编辑，协助编辑部事务。
• More than sixty academic editors handle manuscripts, drawn from Italy, the United States, China, Japan, Brazil, India and Korea, among other countries.六十余位学术编辑处理稿件，来自意大利、美国、中国、日本、巴西、印度与韩国等国家。
• Review is single anonymized, ORCID iDs are required at submission, and the journal accepts free-format manuscripts.评审采用单盲模式，投稿须提供（ORCID），并接受自由格式稿件。
• In 2025 the median time to first decision was 38 days, the acceptance rate was 22 percent, and acceptance to online publication took 24 days.2025 年首次决定中位时间为 38 天，录用率为 22%，录用到在线发表为 24 天。
• Research articles and reviews make up the bulk of output, and purely descriptive studies without mechanistic or translational novelty are screened out early.研究论文与综述构成主体，缺乏机制或转化新意的纯描述性研究会在初筛阶段被拒。